Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1 specific CD4 T cell and antigen-presenting cell functions

Journal of Virology

Volumn 88, Issue 5, 2014, Pages 2508-2518

  Porichis, Filippos ^a   Hart, Meghan G ^a   Zupkosky, Jennifer ^a   Barblu, Lucie ^a,b   Kwon, Douglas S ^a   McMullen, Ashley ^a   Brennan, Thomas ^a   Ahmed, Rafi ^c,d   Freeman, Gordon J ^e   Kavanagh, Daniel G ^a   Kaufmann, Daniel E ^a,b,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR ALPHA; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; PROGRAMMED DEATH 1 LIGAND 1;

ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME REGULATION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; UPREGULATION; VIRUS REPLICATION;

ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD274; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; EPITOPES, T-LYMPHOCYTE; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-10 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MONOCYTES; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION;

EID: 84896729257     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02034-13     Document Type: Article

References (43)

1. Wherry EJ. 2011. T cell exhaustion. Nat. Immunol. 12:492-499.
2. Porichis F, Kwon DS, Zupkosky J, Tighe DP, McMullen A, Brockman MA, Pavlik DF, Rodriguez-Garcia M, Pereyra F, Freeman GJ, Kavanagh DG, Kaufmann DE. 2011. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood 118:965-974. http://dx.doi.org/10.1182/blood-2010-12-328070.
3. Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, Palmer S, Brockman M, Rathod A, Piechocka-Trocha A, Baker B, Zhu B, Le Gall S, Waring MT, Ahern R, Moss K, Kelleher AD, Coffin JM, Freeman GJ, Rosenberg ES, Walker BD. 2007. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8:1246-1254. http://dx.doi.org/10.1038/ni1515.
4. D'Souza M, Fontenot AP, Mack DG, Lozupone C, Dillon S, Meditz A, Wilson CC, Connick E, Palmer BE. 2007. Programmed death 1 expression on HIV-specific CD4+T cells is driven by viral replication and associated with T cell dysfunction. J. Immunol. 179:1979-1987.
5. Kassu A, Marcus RA, D'Souza MB, Kelly-McKnight EA, Golden-Mason L, Akkina R, Fontenot AP, Wilson CC, Palmer BE. 2010. Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection. J. Immunol. 185:3007-3018. http://dx.doi.org/10.4049/jimmunol.1000156.
6. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, Vanderford TH, Chennareddi L, Silvestri G, Freeman GJ, Ahmed R, Amara RR. 2009. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458: 206-210. http://dx.doi.org/10.1038/nature07662.
7. Kwon DS, Angin M, Hongo T, Law KM, Johnson J, Porichis F, Hart MG, Pavlik DF, Tighe DP, Kavanagh DG, Streeck H, Addo MM, Kaufmann DE. 2012. CD4+ CD25+ regulatory T cells impair HIV-1- specific CD4 T cell responses by upregulating interleukin-10 production in monocytes. J. Virol. 86:6586-6594. http://dx.doi.org/10.1128/JVI.06251-11.
8. Stylianou E, Aukrust P, Kvale D, Müller F, Frland SS. 1999. IL-10 in HIV infection: increasing serum IL-10 levels with disease progression- down-regulatory effect of potent anti-retroviral therapy. Clin. Exp. Immunol. 116:115-120.
9. Clerici M, Wynn TA, Berzofsky JA, Blatt SP, Hendrix CW, Sher A, Coffman RL, Shearer GM. 1994. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J. Clin. Invest. 93:768-775. http://dx.doi.org/10.1172/JCI117031.
10. Brockman MA, Kwon DS, Tighe DP, Pavlik DF, Rosato PC, Sela J, Porichis F, Le Gall S, Waring MT, Moss K, Jessen H, Pereyra F, Kavanagh DG, Walker BD, Kaufmann DE. 2009. IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood 114:346-356. http://dx.doi.org/10.1182/blood-2008-12-191296.
11. Brooks DG, Ha SJ, Elsaesser H, Sharpe AH, Freeman GJ, Oldstone MB. 2008. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc. Natl. Acad. Sci. U. S. A. 105:20428-20433. http://dx.doi.org/10.1073/pnas.0811139106.
12. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA, Wherry EJ. 2009. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10:29-37. http://dx.doi.org/10.1038/ni.1679.
13. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. 2013. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369:122-133. http://dx.doi.org/10.1056/NEJMoa1302369.
14. Yamamoto T, Price DA, Casazza JP, Ferrari G, Nason M, Chattopadhyay PK, Roederer M, Gostick E, Katsikis PD, Douek DC, Haubrich R, Petrovas C, Koup RA. 2011. Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+T-cell exhaustion in HIV infection. Blood 117:4805-4815. http://dx.doi.org/10.1182/blood-2010-11-317297.
15. Frentsch M, Arbach O, Kirchhoff D, Moewes B, Worm M, Rothe M, Scheffold A, Thiel A. 2005. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat. Med. 11:1118- 1124. http://dx.doi.org/10.1038/nm1292.
16. Chattopadhyay PK, Yu J, Roederer M. 2006. Live-cell assay to detect antigen-specific CD4+ T-cell responses by CD154 expression. Nat. Protoc. 1:1-6. http://dx.doi.org/10.1038/nprot.2006.1.
17. Chattopadhyay PK, Yu J, Roederer M. 2005. A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat. Med. 11:1113-1117. http://dx.doi.org/10.1038/nm1293.
18. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350-354. http://dx.doi.org/10.1038/nature05115.
19. Francisco LM, Sage PT, Sharpe AH. 2010. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236:219-242. http://dx.doi.org/10.1111/j.1600-065X.2010.00923.x.
20. Saraiva M, O'Garra A. 2010. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10:170-181. http://dx.doi.org/10.1038/nri2711.
21. Porichis F, Hart MG, Zupkosky J, Barblu L, Kaufmann DE. 2013. In vitro assay to evaluate the impact of immunoregulatory pathways on HIVspecific CD4 T cell effector function. J. Vis. Exp. 2013:e50821. http://dx.doi.org/10.3791/50821.
22. Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, Greenfield EA, Liang SC, Sharpe AH, Lichtman AH, Freeman GJ. 2003. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur. J. Immunol. 33:3117-3126. http://dx.doi.org/10.1002/eji.200324270.
23. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, Saudemont A, Quesnel B. 2007. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEKdependent pathway. Blood 110:296-304. http://dx.doi.org/10.1182/blood-2006-10-051482.
24. Berthon C, Driss V, Liu J, Kuranda K, Leleu X, Jouy N, Hetuin D, Quesnel B. 2010. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferongamma and can be reversed using MEK inhibitors. Cancer Immunol. Immunother. 59:1839-1849. http://dx.doi.org/10.1007/s00262-010-0909-y.
25. Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, Belz GT. 2004. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat. Immunol. 5:1143-1148. http://dx.doi.org/10.1038/ni1129.
26. Wagner DH, Jr, Stout RD, Suttles J. 1994. Role of the CD40-CD40 ligand interaction in CD4+ T cell contact-dependent activation of monocyte interleukin-1 synthesis. Eur. J. Immunol. 24:3148-3154. http://dx.doi.org/10.1002/eji.1830241235.
27. Zhang R, Lifson JD, Chougnet C. 2006. Failure of HIV-exposed CD4+ T cells to activate dendritic cells is reversed by restoration of CD40/CD154 interactions. Blood 107:1989-1995. http://dx.doi.org/10.1182/blood-2005-07-2731.
28. Trinchieri G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3:133-146. http://dx.doi.org/10.1038/nri1001.
29. Chehimi J, Starr SE, Frank I, D'Andrea A, Ma X, MacGregor RR, Sennelier J, Trinchieri G. 1994. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J. Exp. Med. 179:1361- 1366. http://dx.doi.org/10.1084/jem.179.4.1361.
30. Chougnet C, Wynn TA, Clerici M, Landay AL, Kessler HA, Rusnak J, Melcher GP, Sher A, Shearer GM. 1996. Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus. J. Infect. Dis. 174:46-53. http://dx.doi.org/10.1093/infdis/174.1.46.
31. O'Garra A, Murphy KM. 2009. From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce T(H)1 development. Nat. Immunol. 10:929-932. http://dx.doi.org/10.1038/ni0909-929.
32. Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. 2012. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 209:1201-1217. http://dx.doi.org/10.1084/jem.20112741.
33. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. 2001. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl. Acad. Sci. U. S. A. 98:13866-13871. http://dx.doi.org/10.1073/pnas.231486598.
34. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. 2001. Interleukin- 10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683- 765. http://dx.doi.org/10.1146/annurev.immunol.19.1.683.
35. Brooks DG, Walsh KB, Elsaesser H, Oldstone MB. 2010. IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection. Proc. Natl. Acad. Sci. U. S. A. 107:3018-3023. http://dx.doi.org/10.1073/pnas.0914500107.
36. Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, Hill BJ, Noto A, Ancuta P, Peretz Y, Fonseca SG, Van Grevenynghe J, Boulassel MR, Bruneau J, Shoukry NH, Routy JP, Douek DC, Haddad EK, Sekaly RP. 2010. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat. Med. 16:452-459. http://dx.doi.org/10.1038/nm.2106.
37. Rodríguez-García M, Porichis F, de Jong OG, Levi K, Diefenbach TJ, Lifson JD, Freeman GJ, Walker BD, Kaufmann DE, Kavanagh DG. 2011. Expression of PD-L1 and PD-L2 on human macrophages is upregulated by HIV-1 and differentially modulated by IL-10. J. Leukoc. Biol. 89:507-515. http://dx.doi.org/10.1189/jlb.0610327.
38. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:2443-2454. http://dx.doi.org/10.1056/NEJMoa1200690.
39. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366:2455-2465. http://dx.doi.org/10.1056/NEJMoa1200694.
40. Lafeuillade A. 2012. Eliminating the HIV reservoir. Curr. HIV/AIDS Rep. 9:121-131. http://dx.doi.org/10.1007/s11904-012-0115-y.
41. Ansari AA, Mayne AE, Sundstrom JB, Bostik P, Grimm B, Altman JD, Villinger F. 2002. Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251- infected rhesus macaques. J. Virol. 76:1731-1743. http://dx.doi.org/10.1128/JVI.76.4.1731-1743.2002.
42. Watanabe N, Sypek JP, Mittler S, Reimann KA, Flores-Villanueva P, Voss G, Lord CI, Letvin NL. 1998. Administration of recombinant human interleukin 12 to chronically SIVmac-infected rhesus monkeys. AIDS Res. Hum. Retroviruses 14:393-399. http://dx.doi.org/10.1089/aid.1998.14.393.
43. Nakanishi Y, Lu B, Gerard C, Iwasaki A. 2009. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 462:510-513. http://dx.doi.org/10.1038/nature08511.